P38-α MAPK-IN-5

P38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research[1].

Product Specifications

CAS Number

[1443242-46-3]

UNSPSC

12352005

Hazard Statement

H272

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/p38-α-mapk-in-5.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H]1CC[C@H](C2=C1C=CC=C2)OC(C=C3)=CN4C3=NN=C4N5[C@H](CCCC5)C)NC6=CC(C(C)(C)C)=NN6C7=CN(N=C7)CCN(C)C

Molecular Formula

C37H49N11O2

Molecular Weight

679.86

Precautions

P210-P220-P280-P370+P378-P501

References & Citations

[1]Elisabetta Armani, et al. Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory Diseases. J Med Chem. 2022 May 26;65 (10) :7170-7192.